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Introduction {#sec001}
============

Hepatocellular carcinoma (HCC) is a major cancer worldwide,\[[@pone.0155744.ref001]\] and its incidence is expected to increase.\[[@pone.0155744.ref002]\] Despite recent advances in resection and ablation techniques, the recurrence rate after initial treatment remains high and the prognosis of patients with HCC is generally unfavorable.\[[@pone.0155744.ref003], [@pone.0155744.ref004]\] In addition, chemotherapy for recurrent HCC after surgical resection is relatively ineffective.\[[@pone.0155744.ref005]\]

To manage treatment-refractory cancers, including HCC, therapies are being designed to specifically target the immune system rather than cancer cells.\[[@pone.0155744.ref006]\] Immune cells have both antitumorigenic and protumorigenic activities, with the latter predominating in patients with non-eliminated, clinically detectable tumors.\[[@pone.0155744.ref007]\] The roles of inflammatory cell types in tumor immunity have been assessed. For example, cytotoxic T cells exert antitumor activity, whereas tumor-infiltrating macrophages and regulatory T cells repress such activity.\[[@pone.0155744.ref008]\] Immune-targeted therapies reinforce antitumor response or prevent inhibitory activity. The degree of immune cell infiltration has prognostic value in many types of cancer.\[[@pone.0155744.ref006]\] Tumor infiltrative lymphocytes (TILs) have generally been associated with favorable prognosis.\[[@pone.0155744.ref009]\] More specifically, different types of infiltrative lymphocytes have different prognostic values.\[[@pone.0155744.ref008]\]

Several studies have analyzed the prognostic significance of immune cell types in patients with HCC. For example, infiltration of CD8-positive T cells has been associated with good prognosis,\[[@pone.0155744.ref010]\] whereas infiltration of Foxp3-positive T cells has been associated with poor prognosis.\[[@pone.0155744.ref011], [@pone.0155744.ref012]\] However, the immunohistochemical procedures required for these analyses may be difficult to implement in routine diagnostic practice. In addition, considering that TILs have cell-type-dependent roles, it is important to determine the general roles and significance of TILs. To our knowledge, however, few studies of HCC have focused on the prognostic significance of TILs from a broad point of view. Wada et al.\[[@pone.0155744.ref013]\] revealed that massive lymphocyte infiltration was associated with better prognosis in patients with small HCC after surgical resection. Unitt et al.\[[@pone.0155744.ref014]\] showed that mild to moderate lymphocytic infiltration correlated with better prognosis after liver transplantation for HCC. These studies, however, did not provide sufficient evidence on the clinicopathologic significance of TILs in patients with HCCs treated by surgical resection, the primary curative treatment for solitary HCC of any size.\[[@pone.0155744.ref015]\]

In addition to lymphocyte infiltration, accompanied plasma cell infiltration has been reported in several types of cancer, including HCC \[[@pone.0155744.ref013], [@pone.0155744.ref016]\]. Though the role of infiltrative plasma cells remains controversial, a recent article described their characteristics, in particular their role in producing IgG4 \[[@pone.0155744.ref017]\].

In this study, we assessed intratumoral lymphoplasmacytic infiltration in more than 500 solitary HCCs by examining hematoxylin and eosin-stained (H&E) slides to precisely determine the clinicopathologic significance of intratumoral lymphoplasmacytic infiltration in HCC.

Materials and Methods {#sec002}
=====================

Patients {#sec003}
--------

This retrospective analysis included consecutive patients with HCC who underwent initial surgical resection at the University of Tokyo Hospital from January 1, 1995 to December 31, 2011. Patients who underwent preoperative transarterial therapy or portal embolization were included only if a sufficient portion of the tumor remained viable. To precisely evaluate tumor prognosis, only patients with solitary HCCs, with or without intrahepatic metastasis, were included, whereas patients with multicentric HCCs\[[@pone.0155744.ref018]\] and those undergoing resection for liver transplantation were excluded.

Clinical data {#sec004}
-------------

Evaluation of patient records was used to determine baseline demographic and clinical data, including patient age, sex, and serum data immediately before surgery; status of hepatitis virus infection; presence or absence of diabetes mellitus; and history of heavy alcohol consumption (≥ 80 g/day). All patients were regularly screened for HCC recurrence by monitoring plasma tumor markers, ultrasonography, and computed tomography. Recurrence was defined as the appearance of a new lesion with radiological features compatible with HCC. Overall survival was defined as the interval between the date of surgery and the date of death, and recurrence-free survival was defined as the interval between the date of surgery and the date of recurrence.

Histologic review {#sec005}
-----------------

Pathology reports and all tissue slides from all patients were reviewed. Tumor size, histologic grade, presence or absence of microvascular invasion, bile duct involvement, and intrahepatic or lymph node metastasis were re-evaluated. Other factors recorded included the presence or absence of steatosis in ≥ 5% of tumor cells, prominent interstitial fibrosis at least in one low-power field, prominent neutrophilic infiltration, and tumor necrosis. In most of these patients, these histologic factors had been evaluated in our previous study.\[[@pone.0155744.ref019]\]

Significant lymphoplasmacytic infiltration was defined in this study as dense multifocal or diffuse lymphoplasmacytic infiltration in two or more fields under low power magnification (×4 objective). Perinecrotic areas were excluded from the assessment of inflammatory cells. HCCs with and without significant lymphoplasmacytic infiltration were assigned, respectively, to the HCC with lymphoplasmacytic infiltration (HCC-LI) group and the HCC with no lymphoplasmacytic infiltration (HCC-NLI) group.

The fibrosis stages of background liver in patients with and without viral hepatitis were evaluated according to the METAVIR system\[[@pone.0155744.ref020]\] and the Nonalcoholic Steatohepatitis Clinical Research Network (NASH-CRN) scoring system,\[[@pone.0155744.ref021]\] respectively. Advanced fibrosis was defined as stages 3 and 4 in both the METAVIR system and NASH-CRN scoring systems. The presence or absence of steatosis (\> 5%) was also recorded.

Statistical Analysis {#sec006}
--------------------

All statistical analyses were performed using JMP Pro 11 (SAS Institute Inc., Cary, NC, USA). Differences were considered significant at *P* \< 0.05. Categorical data were analyzed using the two-sided Fisher\'s exact test. Quantitative variables were compared using Student's *t* test or the Wilcoxon rank sum test, as appropriate. The Kaplan-Meier method and log-rank test were used to analyze survival. Multivariate Cox proportional hazards regression models were used to control for confounding variables. Multivariate regression analysis was performed using all clinicopathologic variables. For subanalysis (treatment-naïve vs. pretreatment patients), only clinicopathologic variables identified as significant on univariate analyses are included due to limitations regarding data size. The "liver cirrhosis" variable was excluded from multivariate analysis because all patients with cirrhosis were included in the group with advanced fibrosis.

Ethics Statement {#sec007}
----------------

The study protocol was approved by the Medical Research Center Ethics Committee of the University of Tokyo. Clinical samples were collected under the University of Tokyo institutional guidelines for the study of human tissues, with all patients providing written informed consent.

Results {#sec008}
=======

Patient overview {#sec009}
----------------

There were 544 patients, 418 (76.8%) males and 126 (23.2%) females, who met the inclusion criteria of the study. The mean patient age was 64.4 years (range, 13 to 85 years). Hepatitis B and C infections were noted in 116 (21.3%) and 289 (53.1%) patients, respectively, and 143 (26.3%) were negative for hepatitis virus infection. Diabetes mellitus was documented in 139 of 542 patients (25.6%), and 97 of 537 patients (18.1%) had a history of heavy alcohol consumption.

Clinical characteristics of HCC with lymphoplasmacytic infiltration {#sec010}
-------------------------------------------------------------------

Based on our criteria, 216 (39.7%) of the 544 patients were assigned to the HCC-LI group and 328 (60.3%) to the HCC-NLI group. Lymphoplasmacytic infiltration was noted at the tumor periphery, in the interstitium, or within the deep parenchyma of the tumor ([Fig 1A](#pone.0155744.g001){ref-type="fig"}, [S1 Digital Data](#pone.0155744.s001){ref-type="supplementary-material"}. Case 1). Of 216 HCC-LIs, multifocal and diffuse patterns were observed in 162 cases (75.0%) and 54 cases (25.0%), respectively. In particular, three cases showed diffuse lymphoplasmacytic infiltration throughout the tumor, corresponding to lymphoepithelioma-like carcinoma ([Fig 1B](#pone.0155744.g001){ref-type="fig"}, [S1 Digital Data](#pone.0155744.s001){ref-type="supplementary-material"}. Case 2).

![Hepatocellular carcinoma with lymphoplasmacytic infiltration.\
(A) Multifocal infiltration pattern. Scale bar represents 500 μm. (B) Diffuse infiltration pattern throughout the tumor, corresponding to lymphoepithelioma-like carcinoma. Scale bar represents 200 μm.](pone.0155744.g001){#pone.0155744.g001}

The clinical features of the HCC-LI and HCC-NLI groups are summarized in [Table 1](#pone.0155744.t001){ref-type="table"}. Patient age, sex, status of hepatitis virus infection, incidence of diabetes mellitus, and history of heavy alcohol consumption did not differ significantly between the two groups. Of four serum tumor markers, the mean level of protein induced by vitamin K absence or antagonist 2 (PIVKA-2) was significantly lower in the HCC-LI group than in the HCC-NLI group (*P* = 0.022). The percent of patients with Child-Pugh stage B liver function (6.5% vs. 15.5%, *P* = 0.001) and the mean indocyanine green retention rate at 15 minutes (ICGR15) (13.3% vs.15.7%, *P* \< 0.001) were significantly lower in the HCC-LI group than in the HCC-NLI group. Logistic regression analyses indicated that the absence of intratumoral lymphoplasmacytic infiltration was independently predictive of Child-Pugh Stage B and a higher ICGR15 ([Table 2](#pone.0155744.t002){ref-type="table"}). Additionally, the mean serum aspartate aminotransferase (AST) concentration was significantly lower in the HCC-LI group than in the HCC-NLI group (*P* \< 0.001). Significantly fewer patients in the HCC-LI group received preoperative treatment (24.5% vs. 39.3%, *P* \< 0.001).

10.1371/journal.pone.0155744.t001

###### Demographic and clinical features of patients with hepatocellular carcinoma with and without lymphoplasmacytic infiltration.

![](pone.0155744.t001){#pone.0155744.t001g}

  Clinical feature                                                    Tumor type                  
  ------------------------------------------------------------- ----- ------------- ------------- --------------
  Age and Sex                                                                                     
    Age (years)                                                 544                               0.860
      \< 65                                                     237   93            144           
      \> = 65                                                   307   123           184           
    Sex                                                         544                               0.535
      Male                                                      418   163           255           
      Female                                                    126   53            73            
  Virus Infection                                                                                 
    HBs-Ag                                                      544                               1.000
      Positive                                                  116   46            70            
      Negative                                                  428   170           258           
    HCV-Ab                                                      544                               0.861
      Positive                                                  288   113           175           
      Negative                                                  256   103           153           
  Diabetes mellitus                                             542                               0.616
    Present                                                     139   58            81            
    Absent                                                      403   158           245           
  History of heavy alcohol consumption(≥ 80g per day)           537                               0.495
    Present                                                     97    42            55            
    Absent                                                      440   174           266           
  Serum tumor marker                                                                              
    AFP \[ng/ml, median (IQR)\]                                 544   27 (448)      17 (234)      0.292
    PIVKA-2 \[mAU/ml, median (IQR)\]                            539   79 (680)      136 (2180)    **0.022**
    CEA \[ng/ml, median (IQR)\]                                 497   3.0 (3.0)     3.4 (3.2)     0.085
    CA19-9 \[U/ml, median (IQR)\]                               490   16 (21)       17 (22)       0.631
  Liver Function                                                                                  
    Child-Pugh stage                                            544                               **0.001**
      A                                                         479   202           277           
      B                                                         65    14            51            
    ICGR15 \[%, mean ± SD\]                                     539   13.3 ± 7.5    15.7 ± 9.7    **\< 0.001**
    Total protein \[U/ml, mean ± SD\]                           544   7.1 ± 0.5     7.0 ± 0.6     0.301
    Albumin \[g/dl, mean ± SD\]                                 544   3.8 ± 0.4     3.6 ± 0.4     **\< 0.001**
    AST \[IU/l, mean ± SD\]                                     544   43.1 ± 23.6   51.7 ± 36.5   **\< 0.001**
    ALT \[IU/l, mean ± SD\]                                     544   43.2 ± 28.7   48.1 ± 35.2   0.079
    Total bilirubin \[mg/dl, mean ± SD\]                        544   0.73 ± 0.32   0.77 ± 0.28   0.238
  Preoperative treatment[\*](#t001fn002){ref-type="table-fn"}   544                               **\< 0.001**
    Present                                                     182   53            129           
    Absent                                                      362   163           199           

HCC-LI, hepatocellular carcinoma with lymphoplasmacytic infiltration; HCC-NLI, hepatocellular carcinoma with no lymphoplasmacytic infiltration; AFP, alpha fetoprotein; PIVKA-2, protein induced by vitamin K absence or antagonist 2; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19--9; ICGR15, indocyanine green retention rate at 15 minutes; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IQR, interquartile range; SD, standard deviation.

\* Including transarterial therapy and portal embolization.

10.1371/journal.pone.0155744.t002

###### Risk factors for liver dysfunction (logistic multivariate analysis).

![](pone.0155744.t002){#pone.0155744.t002g}

                                                       Child Pugh stage B   ICG15 \>15%                                       
  ---------------------------------------------------- -------------------- -------------- ----------- ------- -------------- --------------
  Tumor histology                                                                                                             
  Lymphoplasmacytic infiltration absent (vs present)   2.438                1.248--5.010   **0.009**   1.771   1.164--2.713   **0.008**
  Tumor size \< 50mm (vs ≥ 50mm)                       1.241                0.650--2.389   0.514       1.266   0.800--2.007   0.313
  Histologic grade well and mod (vs por)               1.415                0.688--3.058   0.351       0.954   0.576--1.589   0.857
  Microvascular invasion absent (vs present)           1.061                0.564--2.019   0.854       0.949   0.617--1.456   0.809
  Bile duct invasion absent (vs present)               1.102                0.333--5.031   0.884       0.715   0.308--1.677   0.715
  Intrahepatic metastasis absent (vs present)          1.337                0.635z2.967    0.452       0.954   0.577--1.585   0.855
  Interstitial fibrosis absent (vs present)            1.012                0.553--1.872   0.968       1.178   0.780--1.779   0.436
  Neutrophil infiltration absent (vs present)          1.365                0.439--6.022   0.619       1.632   0.771--3.427   0.198
  Necrosis present (vs absent)                         2.451                1.282--4.792   **0.007**   0.715   0.463--1.101   0.128
  Steatosis present (vs absent)                        1.207                0.593--2.352   0.593       1.475   0.940--2.319   0.678
  Background histology                                                                                                        
  Steatosis absent (vs present)                        1.148                0.629--2.161   0.658       1.414   0.943--2.317   0.094
  Advanced fibrosis present (vs absent)                2.580                1.340--5.336   **0.004**   3.602   2.379--5.548   **\< 0.001**

HR, hazard ratio; CI, confidence interval; por, poorly differentiated; well, well differentiated; mod, moderately differentiated.

Advanced fibrosis corresponds to stages 3 and 4 in the METAVIR system and NASH-CRN scoring systems.

Pathologic Features of HCC with lymphoplasmacytic infiltration {#sec011}
--------------------------------------------------------------

The pathologic features of HCC-LIs and HCC-NLIs are summarized in [Table 3](#pone.0155744.t003){ref-type="table"}. Tumors in the HCC-LI group were significantly smaller in size than those in the HCC-NLI group (43 ± 29 mm vs. 58 ± 42 mm, *P* \< 0.001), but there were no between-group differences in histologic grade, rates of microvascular invasion, bile duct invasion, or intrahepatic metastasis. Prominent neutrophilic infiltration (12.5% vs. 3.7%, *P* \< 0.001), interstitial fibrosis (76.4% vs. 33.5%, *P* \< 0.001) and tumor steatosis (30.6% vs. 17.7%, *P* \< 0.001) were significantly more frequent in the HCC-LI group than in the HCC-NLI group, whereas tumor necrosis was significantly less frequent (49.1% vs. 60.7%, *P* = 0.008). The rates of steatosis, advanced fibrosis, and liver cirrhosis in background liver did not differ significantly between the two groups.

10.1371/journal.pone.0155744.t003

###### Pathologic features of hepatocellular carcinoma with and without lymphoplasmacytic infiltration.

![](pone.0155744.t003){#pone.0155744.t003g}

  Pathologic feature                                             Tumor type         
  -------------------------------------------------------- ----- ------------ ----- --------------
  Tumor                                                                             
  Size (mm)                                                                         **\< 0.001**
    \< 50                                                  332   152          180   
    ≥ 50                                                   212   64           148   
  Histologic grade                                                                  0.152
    Well differentiated                                    76    32           44    
    Moderately differentiated                              363   151          212   
    Poorly differentiated                                  105   33           72    
  Microvascular invasion                                                            0.160
    Present                                                286   122          164   
    Absent                                                 258   94           164   
  Bile duct invasion                                                                0.321
    Present                                                28    14           14    
    Absent                                                 516   202          314   
  Intrahepatic metastasis                                                           0.914
    Present                                                113   44           69    
    Absent                                                 431   172          259   
  Neutrophil infiltration                                                           **\< 0.001**
    Present                                                39    27           12    
    Absent                                                 505   189          316   
  Necrosis                                                                          **0.008**
    Present                                                305   106          199   
    Absent                                                 239   110          129   
  Interstitial fibrosis                                                             **\< 0.001**
    Present                                                275   165          110   
    Absent                                                 269   51           218   
  Steatosis                                                                         **\< 0.001**
    Present                                                124   66           58    
    Absent                                                 420   150          270   
  Background liver                                                                  
  Steatosis (\>5%)                                                                  0.452
    Present                                                173   73           100   
    Absent                                                 371   143          228   
  Advanced fibrosis[\*](#t003fn002){ref-type="table-fn"}                            0.165
    Present                                                360   135          225   
    Absent                                                 184   81           103   
  Liver cirrhosis                                                                   0.126
    Present                                                208   74           134   
    Absent                                                 336   142          194   

HCC-LI, hepatocellular carcinoma with lymphoplasmacytic infiltration; HCC-NLI, hepatocellular carcinoma with no lymphoplasmacytic infiltration.

\* Corresponding to stages 3 and 4 in the METAVIR system and NASH-CRN scoring systems.

Prognosis {#sec012}
---------

The median follow-up period for the 544 patients was 52.7 months (range 0.8--168.5 months). Their cumulative overall and recurrence-free survival rates at five years were 42.7% and 19.0%, respectively. Kaplan-Meier analyses showed significantly longer overall and recurrence-free survival of patients in the HCC-LI group than in the HCC-NLI group (*P* \< 0.001 each by log-rank tests) ([Fig 2](#pone.0155744.g002){ref-type="fig"}). Multivariate Cox regression analyses showed that intratumoral lymphoplasmacytic infiltration, microvascular invasion, intrahepatic metastasis, tumor steatosis, and advanced fibrosis of background liver were independently prognostic of overall survival, whereas intratumoral lymphoplasmacytic infiltration, tumor size, microvascular invasion, intrahepatic metastasis, and advanced fibrosis of background liver were independently prognostic of recurrence-free survival ([Table 4](#pone.0155744.t004){ref-type="table"}).

![Kaplan--Meier analysis of survival in patients with HCC with and without significant lymphoplasmacytic infiltration.\
HCCs with lymphoplasmacytic infiltration (HCC-LIs) show significantly better prognosis in overall (A) and recurrence-free (B) survivals than HCCs with lymphoplasmacytic infiltration (HCC-NLIs).](pone.0155744.g002){#pone.0155744.g002}

10.1371/journal.pone.0155744.t004

###### Factors prognostic of overall and recurrence-free survival in patients with solitary hepatocellular carcinoma.

![](pone.0155744.t004){#pone.0155744.t004g}

                                                                               Overall survival   Recurrence-free survival                                                                                                                     
  ---------------------------------------------------------------------------- ------------------ -------------------------- -------------- ------- -------------- -------------- ------- -------------- -------------- ------- -------------- --------------
  Tumor histology                                                                                                                                                                                                                              
  Lymphoplasmacytic infiltration absent (vs present)                           1.850              1.377--2.518               **\< 0.001**   1.731   1.240--2.444   **\< 0.001**   1.565   1.271--1.936   **\< 0.001**   1.567   1.242--1.983   **\< 0.001**
  Size ≥ 50mm (vs \< 50mm)                                                     1.992              1.509--2.626               **\< 0.001**   1.269   0.891--1.810   0.187          1.836   1.495--2.246   **\< 0.001**   1.332   1.036--1.714   **0.026**
  Histologic grade por (vs well and mod)                                       2.163              1.580--2.922               **\< 0.001**   1.299   0.906--1.845   0.153          1.476   1.147--1.878   **0.003**      0.913   0.684--1.209   0.529
  Microvascular invasion present (vs absent)                                   2.200              1.659--2.936               **\< 0.001**   1.642   1.167--2.309   **0.005**      1.767   1.443--2.169   **\< 0.001**   1.436   1.128--1.826   **0.003**
  Bile duct invasion present (vs absent)                                       2.113              1.217--3.410               **0.010**      1.442   0.795--2.463   0.218          1.649   1.051--2.455   **0.031**      1.290   0.798--1.997   0.287
  Intrahepatic metastasis present (vs absent)                                  2.574              1.891--3.463               **\< 0.001**   1.728   1.217--2.438   **0.002**      2.905   2.294--3.650   **\< 0.001**   2.196   1.685--2.844   **\< 0.001**
  Interstitial fibrosis absent (vs present)                                    1.306              0.991--1.726               0.057          1.037   0.759--1.425   0.819          1.136   0.928--1.390   0.216          0.963   0.768--1.210   0.746
  Neutrophil infiltration absent (vs present)                                  1.017              0.631--1.765               0.948          1.087   0.634--1.983   0.772          1.162   0806--1.746    0.436          1.209   0.808--1.878   0.367
  Necrosis present (vs absent)                                                 1.845              1.391--2.464               **\< 0.001**   1.141   0.815--1.601   0.444          1.690   1.377--2.079   **\< 0.001**   1.172   0.915--1.500   0.208
  Steatosis absent (vs present)                                                2.005              1.369--3.052               **\< 0.001**   1.632   1.090--2.529   **0.016**      1.314   1.030--1.697   **0.027**      1.169   0.900--1.536   0.246
  Background histology                                                                                                                                                                                                                         
  Steatosis absent (vs present)                                                1.360              1.005--1.867               **0.045**      1.127   0.816--1.577   0.473          1.119   0.903--1.396   0.306          1.091   0.869--1.377   0.458
  Advanced fibrosis[\*](#t004fn002){ref-type="table-fn"} present (vs absent)   1.620              1.180--2.269               **0.003**      1.933   1.377--2.762   **\< 0.001**   1.386   1.114--1.727   **0.003**      1.553   1.232--1.971   **\< 0.001**
  Liver cirrhosis present (vs absent)                                          1.279              0.969--1.687               0.082                                                1.294   1.053--1.586   **0.014**                             

HR, hazard ratio; CI, confidence interval; por, poorly differentiated; well, well differentiated; mod, moderately differentiated.

\* Corresponding to stages 3 and 4 in the METAVIR system and NASH-CRN scoring systems.

Discussion {#sec013}
==========

This study showed that lymphoplasmacytic infiltration in HCC, defined by our simple criteria, was significantly associated with several clinical and pathologic features. Most importantly, this infiltration was independently prognostic for overall and recurrence-free survival, with absence of infiltration showing high hazard ratios for poor prognosis.

The mean serum level of PIVKA2 was lower in the HCC-LI group than in the HCC-NIL group. The previously demonstrated correlation of this tumor marker with tumor size,\[[@pone.0155744.ref022]\] confirmed in the present study (data not shown), indicated that the lower level of PIVKA2 in the HCC-LI group was largely attributable to the significantly smaller sizes of these tumors. We speculated that the notably better liver function in patients in the HCC-LI group was also related to the smaller sizes of these tumors (larger volume of residual liver). Logistic multivariate analysis, however, showed that intratumoral lymphoplasmacytic infiltration was an independent negative predictor of Child-Pugh stage B and high ICGR15, indicating that liver function was directly associated with the extent of inflammatory infiltration. Presumably, patients with good liver function tend to retain anti-tumor immunity, whereas those with impaired liver function are prone to lose that reactivity. This hypothesis is in agreement with the finding that patients with advanced liver disease are frequently in an immunocompromised state.\[[@pone.0155744.ref023]\]

The lower incidence of preoperative treatment in the HCC-LI group was likely due to the smaller tumor sizes in these patients, because tumor size and estimated residual liver volume have been identified as major determinants of preoperative treatment in our clinical practice. The higher incidence of tumor necrosis in the HCC-NLI group probably resulted from frequent preoperative treatment.

Pathologically, significantly smaller tumor sizes in the HCC-LI group may reflect inflammatory responses that suppressed tumor growth. Patients in both the HCC-LI and HCC-NLI groups, at least those infected with hepatitis virus, had been regularly and similarly screened for tumor development, suggesting that tumors with inflammatory infiltration grew more slowly. Alternatively, tumors may acquire anti-inflammatory (anti-immune) properties when they grow larger. Further basic studies are needed to determine the mechanism by which inflammatory infiltration influences tumor growth.

The cause of the higher frequency of tumor steatosis in the HCC-LI group may be multifactorial. It may be related to the smaller-size tumors in this group, because small, early-stage HCCs frequently manifest fatty changes.\[[@pone.0155744.ref018]\] The causal relationship between intracellular lipid accumulation and inflammatory reaction, as observed in patients with non-alcoholic fatty liver disease,\[[@pone.0155744.ref024]\] suggests that tumor steatosis may have induced inflammatory reaction. A recent study demonstrating that inflammatory cells induced hepatocellular steatosis in a mouse model of non-alcoholic steatohepatitis\[[@pone.0155744.ref025]\] indicates another possibility.

Frequent interstitial fibrosis of HCC-LIs is quite plausible, as hepatic fibrosis generally results from the immune reactive process.\[[@pone.0155744.ref026]\] Hepatic stellate cells are thought to play crucial roles in fibrogenesis.\[[@pone.0155744.ref027]\] These cells also play an important role in fibrosis in HCC, interacting with tumor cells and inflammatory cells.\[[@pone.0155744.ref028]\]

The present study, analyzing a large cohort of patients with HCC, showed that intratumoral lymphoplasmacytic infiltration was an independent prognostic factor for survival in patients with HCC. This study confirmed the prognostic significance of histologic features previously shown to be prognostic in patients with HCC, including tumor size, histologic grade, microvascular invasion of tumors, and advanced fibrosis of background liver. Of particular note, absence of infiltration showed the second highest hazard ratio for overall survival, after advanced fibrosis of background liver, and the second highest hazard ratio for recurrence-free survival, after intrahepatic metastasis. Additional subgroup analyses of treatment-naïve vs. pretreatment patients ([S1](#pone.0155744.s003){ref-type="supplementary-material"}--[S5](#pone.0155744.s007){ref-type="supplementary-material"} Tables and [S1 Fig](#pone.0155744.s002){ref-type="supplementary-material"}) showed that HCC-LI cases had better preserved liver function than treatment-naïve cases, while of the pretreatment patients, HCC-LI showed a stronger association with neutrophil infiltration or steatosis. Remarkably, in both the treatment-naïve and pretreatment groups, HCC-LI was associated with better prognosis in terms of both recurrence-free and overall survival as determined using multivariate Cox proportional hazards regression models. These findings indicate that intratumoral lymphoplasmacytic infiltration should be assessed in routine diagnostic practice.

The favorable prognosis of patients with HCC-LI presumably had at least two causes. First, robust antitumor immunity should have inhibited the growth of residual tumor that was not apparent at the time of surgical resection. This mechanism seems responsible for the favorable prognosis of tumors with inflammatory infiltration, which have been shown in cancers of various organs.\[[@pone.0155744.ref009], [@pone.0155744.ref029]\] Additionally, specific conditions associated with hepatocarcinogenesis should be entertained; most patients in this study had advanced chronic liver diseases, and thus were cancer prone. Considering that the rates of liver cirrhosis and advanced fibrosis were similar in the HCC-LI and HCC-NLI groups, patients with HCC-LI, with supposedly healthy immune function, probably exhibited effective antitumorigenic immune reactions to newly developing lesions.

Much remains to be elucidated about the basic mechanisms of tumor immunity. Even the roles of inflammatory cell types have not been sufficiently clarified. In this study, we found that plasma cell infiltration was not infrequently prominent in HCC-LIs, and we therefore described the infiltration as "lymphoplasmacytic infiltration." Compared with T cells, the roles of B cells in tumor immunity are largely unknown. Although numerous studies have shown that B cells promote rather than inhibit tumor development, recent studies have revealed these cells' antitumorigenic roles.\[[@pone.0155744.ref030], [@pone.0155744.ref031]\]

Molecular signatures differentiating HCCs with and without infiltration are also of interest. Genetic aspects of tumors may determine the extent of anti-tumor inflammatory reactions. For example, microsatellite instability is strongly associated with lymphocytic infiltration in colorectal cancers.\[[@pone.0155744.ref032]\] Interestingly, Tan et al.\[[@pone.0155744.ref033]\] demonstrated that HCCs with marked immune cell infiltrate were associated with the S1 molecular subclass, defined by a transcriptome meta-analysis of global HCC populations. Further studies are needed to determine the detailed relationships between the genetic characteristics of HCC and immune cell reactions.

Determining the optimal definition of lymphoplasmacytic infiltration was one of the most challenging issues in this study. We reviewed several definitions, and adopted a definition that was the most straightforward and reproducible. Two pathologists independently evaluated 82 recent three-year cases, and in 69 (84.1%) of them they were in agreement regarding the presence of lymphocytic infiltration. We believe that this classification scheme is currently reasonable and useful, but further research should evaluate more objective definitions that can be used in daily diagnosis.

Conclusions {#sec014}
===========

Intratumoral lymphoplasmacytic infiltration was associated with favorable liver function, as shown by lower incidence of Child-Pugh stage B and lower ICGR15 levels, and with several pathologic features, including smaller tumor size, more frequent interstitial fibrosis, and steatosis of the tumor. Most importantly, infiltration was an independent prognostic factor for overall and recurrence-free survival, with absence of infiltration showing high Cox-hazard ratios for poor prognosis.

Supporting Information {#sec015}
======================

###### Digital slides, including 4 HCCs with lymphoplasmacytic infiltration (HCC-Lis, Case 1--4) and 2 HCCs without lymphoplasmacytic infiltration (HCC-NLIs, Case 5 and 6), are available on our website (<http://plaza.umin.ac.jp/~pathdatabase/index.html>).

Cases 1 and 2 correspond to the cases in [Fig 1A and 1B](#pone.0155744.g001){ref-type="fig"}, respectively. Cases 3 and 4 are additional HCC-LI cases with multifocal and diffuse patterns, respectively.

(PDF)

###### 

Click here for additional data file.

###### Kaplan-Meier analysis shows significantly better prognosis in overall and recurrence-free survival in both treatment-naïve and pretreatment groups in HCCs with lymphoplasmacytic infiltration (HCC-LIs) than HCCs without lymphoplasmacytic infiltration (HCC-NLIs).

(TIF)

###### 

Click here for additional data file.

###### Demographic and clinical features of treatment-naïve and pretreatment HCC with and without lymphoplasmacytic infiltration.

(DOCX)
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Click here for additional data file.

###### Risk factors for liver dysfunction in treatment-naïve HCC (logistic multivariate analysis).

(DOCX)

###### 

Click here for additional data file.

###### Pathologic features of treatment-naïve and pretreatment HCC with and without lymphoplasmacytic infiltration.

(DOCX)

###### 

Click here for additional data file.

###### Factors prognostic of overall and recurrence-free survival in patients with treatment-naïve solitary HCC.

(DOCX)

###### 

Click here for additional data file.

###### Factors prognostic of overall and recurrence-free survival in patients with pretreatment solitary HCC.

(DOCX)

###### 

Click here for additional data file.
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